Aastrom Stands Behind Its Decision To Shift Gears In Late Stages
This article was originally published in The Pink Sheet Daily
The Michigan biotech is undergoing a complete restructuring as it cans its lead program and new management implements a different vision for the company.
You may also be interested in...
The stem cell company will use revenues from the already-marketed products to continue funding the late-stage stem cell therapy in its pipeline and help it build out its commercial organization.
The 27th annual Beyond Borders report shows continued constraints to funding for biotechs, as they cut R&D and deal with a changing development landscape, but VC funding remains resilient.
Jeff Jonas takes over Shire’s newly formed Regenerative Medicine business with plans for rapid growth, replacing Advanced BioHealing’s Kevin Rakin in the role.